Previous Close | 125.10 |
Open | 125.76 |
Bid | 126.44 x 100 |
Ask | 126.79 x 100 |
Day's Range | 124.91 - 127.61 |
52 Week Range | 99.06 - 134.17 |
Volume | |
Avg. Volume | 703,834 |
Market Cap | 7.658B |
Beta (5Y Monthly) | 0.57 |
PE Ratio (TTM) | 17.94 |
EPS (TTM) | 7.06 |
Earnings Date | Nov 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 177.53 |
ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Piper Sandler lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $163 from $166 and keeps an Overweight rating on the shares. The firm notes Jazz shares are down about 30% since the closing of the GW acquisition in May 2021, even with Epidiolex-associated diversification and the success of Xywav. Though Piper is bullish on the transformative potential of the OX2R agonists in sleep/wake, it still envisions a sizable role for oxybate products, particularly in narcolepsy type 2 and i